Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic…
Articles by Marisa Wexler, MS
Since the approval of Trikafta in the U.S., Nationwide Children’s Hospital in Ohio…
A platform to help people with cystic fibrosis (CF) better adhere to inhalation treatment, called the CFHealthHub, led to…
Health Canada has granted priority review to an application that seeks to expand the approval of Trikafta to cover…
Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution,…
Treatment with LungFit GO, an inhaled form of nitric oxide that can be self-administered at home, has so far…
The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic…
The school closures, at-home confinements and other safety measures necessitated by the COVID-19 pandemic have caused less anxiety among children…
Since the introduction of Kalydeco (ivacaftor) in the U.K., marked changes in treatment patterns for cystic fibrosis (CF)…
Bacteria living in the gut are abnormally slow to develop functional abilities in infants with cystic fibrosis (CF), which…